Rosuvastatin reduces ischemia-reperfusion injury in patients with acute coronary syndrome treated with percutaneous coronary intervention

Clinical Cardiology

Volumn 37, Issue 9, 2014, Pages 530-535

  Jiang, Fangyong ^a   Yang, Jin ^a   Zhang, Linchao ^a   Li, Rongshan ^a   Zhuo, Liuan ^a   Sun, Liping ^a   Zhao, Qin ^a  

^a LIUZHOU PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; MALONALDEHYDE; ROSUVASTATIN; SUPEROXIDE DISMUTASE; BIOLOGICAL MARKER; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROTEIN BLOOD LEVEL; REPERFUSION INJURY; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD; CHINA; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CHINA; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MALONDIALDEHYDE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; NATRIURETIC PEPTIDE, BRAIN; PERCUTANEOUS CORONARY INTERVENTION; PYRIMIDINES; STROKE VOLUME; SULFONAMIDES; SUPEROXIDE DISMUTASE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84908289078     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22292     Document Type: Article

References (30)

1. Tcheng JE, Mackay SM. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. Am J Cardiovasc Drugs. 2012;12:83-91.
2. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
3. Katsaros KM, Kastl SP, Zorn G, et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Cardiovasc Interv. 2010;3:90-97.
4. Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med. 2009;47:344-356.
5. Sakuma T, Leong-Poi H, Fisher NG, et al. Further in insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: the role of microthromboemboli. J Am Soc Echocardogr. 2003;16:15-21.
6. Frohlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J. 2013;34:1714-1722.
7. Hanefeld M, Marx N, Pfutzner A, et. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007;49:290-297.
8. Vuolteenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem. 2005;40:1-36.
9. Uraizee A. Failure of superoxide dismutase to limit size of myocardial infarction after 40 minutes of ischemia and 4 days of reperfusion in dogs. Circulation. 1987;75:1237-1248.
10. Roman RM, Camargo PV, Borges FK, et al. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coron Artery Dis. 2010;21:129-136.
11. Liu Y, Su Q, Li L. Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials. Clin Cardiol. 2013;36:E41-E48.
12. Yamasaki T, Koizumi T, Iida S, et al. Benefit of thrombus aspiration for myocardial infarction with ST-segment elevation: analysis by biomarkers of thrombosis and inflammation. Circulation. 2009;120:S926.
13. Herrmann J, Lennon RJ, Barsness GW, et al. High sensitivity Creactive protein and outcomes following percutaneous coronary intervention in contemporary practice. Circ Cardiovasc Interv. 2012;5:783-790.
14. Jiang FY, Sun LP, Yang J. Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011;31:1607-1610.
15. Peters SA, Palmer MK, Grobbee DE. C-reactive protein lowering with Rosuvastatin in the METEOR study. J Intern Med. 2010;268:155-161.
16. Chen M, Li H, Wang Y. Protection by atorvastatin pretreatment in patients undergoing primary percutaneous coronary intervention is associated with the lower levels of oxygen free radicals. J Cardiovasc Pharmacol. 2013;62:320-324.
17. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-segment elevation myocardial infarction-summary article; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-1374.
18. Kim MJ, Jeon DS, Gwon HC, et al. Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea. Clin Cardiol. 2012;35:700-706.
19. Jeong HC, Ahn Y, Hong YJ. Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. Int J Cardiol. 2013;167:1848-1853.
20. Ozacmak VH, Sayan H, Igdem AA, et al. Attenuation of contractile dysfunction by atorvastatin after intestinal is ischemia reperfusion injury in rats. Eur J Pharmacol. 2007;562:138-147.
21. Nissen SE, Tuzcu EM, Schoenhagen P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
22. Schulz E, Gori T, Munzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34:665-673.
23. Biasillo G, Leo M, Della Bona R, et al. Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med. 2010;5:225-233.
24. Turner JG, Rakhmelivich AL, Burdelya L, et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol. 2001;166:89-94.
25. Fujimoto H, Suzuki T, Aizawa K, et al. Processed B-type natriuretic peptide is a biomarker of post interventional restenosis in ischemic heart disease. Clin Chem. 2013;59:1330-1337.
26. Dhaliwal AS, Deswal A, Pritchett A, et al. Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail. 2009;15:293-299.
27. Hirayama A, Kusuoka H, Yamamoto H, et al. Usefulness of plasma brain natriuretic peptide concentration for predicting subsequent left ventricular remodeling after coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol. 2006;98:453-457.
28. Grabowski M, Filipiak KJ, Karpinski G, et al. Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am Heart J. 2004;148:655-662.
29. Kim MK, Chung WY, Cho YS, et al. Serum N-terminal N-terminal pro-B-type natriuretic peptide levels at the time of hospital admission predict of microvascular obstructions after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Interv Cardiol. 2011;24:34-41.
30. Moutzouri E, Liberopoulos EN, Tellis CC, et al. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 231:8-14.